Race Oncology Raises $3.2m at 6% Premium: Is RAC Still a Buy After 87% Rally?

Race Oncology’s (ASX: RAC) latest capital raise sends a strong signal. The company secured A$3.2 million from sophisticated investors at $2.83 per share, a 6% premium to its last close.…

ByUjjwal Maheshwari

18

Nov 2025

Market news

Race Oncology (ASX: RAC) Launches Lung Cancer Program: Buy the Breakout or Wait for a Pullback?

Race Oncology (ASX: RAC) unveiled two new clinical programs, expanding its lead drug RC220 into acute myeloid leukaemia and EGFR-mutated non-small cell lung cancer. For investors tracking the Australian biotech…

ByUjjwal Maheshwari

02

Oct 2025

Healthcare Stocks Tech Stocks Technology

Race Oncology Jumps 23% as Researchers Uncover Key Mechanism Behind Lead Cancer Drug

Race Oncology Soars 23% on Breakthrough Discovery Targeting MYC Race Oncology (ASX: RAC) opened strongly, rising 23 percent after releasing new insights into how its lead cancer drug, bisantrene…

ByCharlie Youlden

22

Dec 2022

Life Sciences

Which ASX health stocks might get FDA approval in 2023?

It is the dream of many ASX health stocks and their investors for their company's device or drug to be approved by the FDA, the USA's medical regulator. This is…